Human endogenous retrovirus onco-exaptation counters cancer cell senescence through calbindin.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
17 07 2023
Historique:
received: 10 08 2022
accepted: 11 05 2023
medline: 21 7 2023
pubmed: 16 5 2023
entrez: 16 5 2023
Statut: epublish

Résumé

Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterize most cancer types and are linked with disease outcomes. However, the underlying processes are incompletely understood. Here, we show that elevated transcription of HERVH proviruses predicted survival of lung squamous cell carcinoma (LUSC) and identified an isoform of CALB1, encoding calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1 expression was initiated in preinvasive lesions and associated with their progression. Calbindin loss in LUSC cell lines impaired in vitro and in vivo growth and triggered senescence, consistent with a protumor effect. However, calbindin also directly controlled the senescence-associated secretory phenotype (SASP), marked by secretion of CXCL8 and other neutrophil chemoattractants. In established carcinomas, CALB1-negative cancer cells became the dominant source of CXCL8, correlating with neutrophil infiltration and worse prognosis. Thus, HERVH-CALB1 expression in LUSC may display antagonistic pleiotropy, whereby the benefits of escaping senescence early during cancer initiation and clonal competition were offset by the prevention of SASP and protumor inflammation at later stages.

Identifiants

pubmed: 37192000
pii: 164397
doi: 10.1172/JCI164397
pmc: PMC10348765
doi:
pii:

Substances chimiques

Calbindins 0
CALB1 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Arthritis Research UK
ID : CC2089
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : CC2041
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : CC2088
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : FC001099
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Auteurs

Jan Attig (J)

Retroviral Immunology.

Judith Pape (J)

Retroviral Immunology.

Laura Doglio (L)

Retroviral Immunology.

Anastasiya Kazachenka (A)

Retroviral Immunology.

Eleonora Ottina (E)

Retroviral Immunology.

George R Young (GR)

Bioinformatics and Biostatistics.

Katey Ss Enfield (KS)

Cancer Evolution and Genome Instability, and.

Iker Valle Aramburu (IV)

Antimicrobial Defence, The Francis Crick Institute, London, United Kingdom.

Kevin W Ng (KW)

Retroviral Immunology.

Nikhil Faulkner (N)

Retroviral Immunology.

William Bolland (W)

Retroviral Immunology.

Venizelos Papayannopoulos (V)

Antimicrobial Defence, The Francis Crick Institute, London, United Kingdom.

Charles Swanton (C)

Cancer Evolution and Genome Instability, and.

George Kassiotis (G)

Retroviral Immunology.
Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH